Gene repair involving in vivo excision of targeting DNA

Details Gene repair involving in vivo excision of targeting DNA Gene repair involving in vivo excision of targeting DNA

2011-06-14

2011-06-14

Kelly, Robert M (Department: 1633)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C514S04400A, C435S320100

Reexamination Certificate

active

07960525

ABSTRACT:
Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof.

REFERENCES:
patent: 5436150 (1995-07-01), Chandrasegaran
patent: 5674499 (1997-10-01), Willemse et al.
patent: 5792632 (1998-08-01), Dujon et al.
patent: 5830729 (1998-11-01), Jaisser et al.
patent: 5962327 (1999-10-01), Dujon et al.
patent: 6238924 (2001-05-01), Dujon et al.
patent: 7098031 (2006-08-01), Choulika et al.
patent: 7285538 (2007-10-01), Choulika et al.
patent: 7629326 (2009-12-01), Choulika et al.
patent: 2002/0107214 (2002-08-01), Choulika et al.
patent: 2002/0110898 (2002-08-01), Choulika et al.
patent: 2004/0019002 (2004-01-01), Choulika et al.
patent: WO 96/14408 (1996-05-01), None
patent: WO 00/46386 (2000-08-01), None
Notification of Transmittal of the International Search Report (ISR) or the Declaration, with ISR, PCT/US2000/02949, mailed Jul. 6, 2000.
Invitation to Restrict or to Pay Additional Fees, PCT/US2000/02949, mailed Nov. 16, 2000.
Written Opinion, PCT/US2000/02949, mailed Jan. 26, 2001.
Notification of Transmittal of the International Preliminary Examination Report (IPER), with IPER, PCT/US2000/02949, mailed May 23, 2001.
Choulika, A. et al., “The Yeast I-SCE I Meganuclease Induces Site-Directed Chromosomal Recombination in Mammalian Cells,”C.R. Acad. Sci. III, 317:1013-1019 (1994).
Cohen-Tannoudji, M., et al., “I-Scel-Induced Gene Replacement at a Natural Locus in Embryonic Stem Cells,”Mol. Cell. Biol.18(3):1444-1448 (Mar. 1998).
Choulika, A. et al., “Induction of Homologous Recombination in Mammalian Chromosomes by Using the I-SceI System of Saccharomyces cerevisiae,”Molecular and Cellular Biology, 15(4):1968-1973 (1995).
Smith, J. et al., “A Detailed Study of the Substrate Specificity of a Chimeric Restriction Enzyme,”Nucleic Acids Res., 27(2):674-681 (Jan. 15, 1999).
Nahon, E. and Raveh, D., “Targeting a Truncated Ho-Endonuclease of Yeast to Novel DNA Sites with Foreign Zinc Fingers,”Nucleic Acids Res., 26(5):1233-1239 (1998).
Kim, Y.G. et al., “Hybrid Restriction Enzymes: Zinc Finger Fusions to Fok I Cleavage Domain,”Proc. Natl. Acad. Sci. USA, 93(3):1156-1160 (1996).
Anderson, W.F., “Human Gene Therapy,”Nature, 392:25-30 (Apr. 30, 1998).
Nishikawa, M. et al., “Nonviral Vectors in the Millennium: Delivery Barriers in Gene Transfer,”Human Gene Therapy, 12:861-870 (2001).
Rozenberg, Y. et al., “Alternative Gene Delivery,”S.T.P. Pharma Sciences,11:21-30 (2001).
Balicki, D. et al., “Gene Therapy of Human Disease,”Medicine, 81:69-86 (2002).
Orkin, S. H. and Motulsky, A.G., “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy”, National Institutes of Health, 1-41 (Dec. 7, 1995).
Verma, I. M. et al., “Gene Therapy-Promises, Problems and Prospects,”Nature, 389:239-242 (1997).
Ross, G. et al., “Gene Therapy in the United States: A Five-Year Status Report,”Human Gene Therapy, 7:1781-1790 (1996).
Marshall, E., “Gene Therapy's Growing Pains,”Science, 269:1050-1055 (1995).
“There are Common Motifs in Many Sequence-specific DNA-binding Proteins,” InMolecular Biology of the Cell, 2nded. Alberts, B. et al.(eds). (Garland Publishing, New York), Chap. 9, p. 490 (1989).
Promega “Revolutions in Science,” 1993/1994 Catalog, p. 20.
Belfort, M. and Roberts, R.J., “Homing endonucleases: keeping the house in order,”Nucleic Acids Res.25(17): 3379-3388 (1997).
Grindl, W., et al., “The protein splicing domain of the homing endonuclease PI-Scel is responsible for specific DNA binding,”Nucleic Acids Res.26(8): 1857-1862 (Apr. 15, 1998).
Pósfai, G., et al., “Markerless gene replacement inEscherichia colistimulated by a double-strand break in the chromosome,”Nucleic Acids Res.27(22): 4409-4415 (Nov. 15, 1999).
Plessis, A., et al., “Site-Specific Recombination Determined by I-Scel, a Mitochondrial Group I Intron-Encoded Endonuclease Expressed in the Yeast Nucleus,”Genetics130:451-460 (Mar. 1992).
Rouet, P., et al., “Expression of a Site-Specific Endonuclease Stimulates Homologous Recombination in Mammalian Cells,”Proc. Natl. Acad. Sci. USA91:6064-6068 (Jun. 1994).
Gunzburg, W.H. and Salmons, B., “Virus Vector Design in Gene Therapy,” Mol. Med. Today 1(9) Abstract (Dec. 1995).
Góorecki, D.C., “Prospects and Problems of Gene Therapy: An Update,”Expert Opin. Emerging Drugs6(2):187-198 (2001).
Eck, S.L., and Wilson, J.M.,Goodman&Gilman's The Pharmacological Basis of Therapeutics, Ninth Ed., Chapter 5, pp. 77-101, McGraw-Hill, New York, 1996.
Deonarain, M.P., “Ligand-Targeted Receptor-Mediated Vectors for Gene Delivery,” Exp. Opin. Ther. Patents 8(1):53-69 (Jan. 1998).
Kim, Y-G., and Chandrasegaran, S., “Chimeric Restriction Endonuclease,” Proc. Natl. Acad. Sci. USA, 91: 883-887 (1994).
The Children's Medical Center Corporation, et al., PCT/US2000/03014, Invitation to Pay Additional Fees, mailed Jun. 21, 2000, 6 pgs.
The Children's Medical Center Corporation, et al., PCT/US2000/03014, Notification of Transmittal of the International Search Report (ISR) or the Declaration with ISR, mailed Sep. 13, 2000, 11 pgs.
The Children's Medical Center Corporation, et al., PCT/US2000/03014, Written Opinion, mailed Mar. 13, 2001, 6 pgs.
The Children's Medical Center Corporation, et al., PCT/US2000/03014, Notification of Transmittal of the International Preliminary Examination Report (IPER) with IPER, mailed May 25, 2001, 7 pgs.
The Children's Medical Center Corporation, EP 00 908 499.7, Communication, mailed Jan. 19, 2005, 6 pgs.
The Children's Medical Center Corporation, et al., EP 00 908 499.7, Reply, filed Nov. 18, 2005, 7 pgs.
The Children's Medical Center Corporation, et al., EP 00 908 499.7, Summons to attend oral proceedings, mailed Feb. 20, 2007, 8 pgs.
The Children's Medical Center Corporation, et al., EP 00 908 499.7, Response to Summons, filed May 11, 2007, 6 pgs.
The Children's Medical Center Corporation; The Institute Pasteur, Canadian Appl. 2,361,191, Office Action, dated Nov. 13, 2009, 5 pgs.
The Children's Medical Center Corporation, et al, Japan Appl. 2000597445, Office Action, dated Nov. 26, 2009 4 pgs.
The Children's Medical Center Corporation, et al, Japan Appl. 2000597444, Office Action, dated Nov. 25, 2009 4 pgs.
The Children's Medical Center Corporation; The Institute Pasteur, Canadian Appl. 2,360,878, Office Action, dated Aug. 31, 2009, 4 pgs.
The Children's Medical Center Corporation; The Institute Pasteur, Canadian Appl. 2,360,878, Reply, filed Feb. 25, 2010, 18 pgs.
The Children's Medical Center Corporation; The Institute Pasteur, Canadian Appl. 2,360,878, Office Action, dated Jun. 17, 2010, 3 pgs.

Affiliated with

Also associated with

Rating

Gene repair involving in vivo excision of targeting DNA does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Gene repair involving in vivo excision of targeting DNA, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene repair involving in vivo excision of targeting DNA will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2698124